Gilead Sciences (GILD) Advances While Market Declines: Some Information for InvestorsZacks Investment Research • 01/31/26
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026Business Wire • 01/27/26
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast CancerBusiness Wire • 01/21/26
Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth KnowingZacks Investment Research • 01/13/26
Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead's Drug CandidateBusiness Wire • 01/06/26
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 01/06/26
Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital HerpesBusiness Wire • 12/22/25
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients payWSJ • 12/19/25
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for AmericansBusiness Wire • 12/19/25